Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Dow
Johnson and Johnson
Merck
McKinsey

Last Updated: May 27, 2022

Neos Theraps Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for NEOS THERAPS INC, and what generic alternatives to NEOS THERAPS INC drugs are available?

NEOS THERAPS INC has two approved drugs.

There are seven US patents protecting NEOS THERAPS INC drugs.

There are seven patent family members on NEOS THERAPS INC drugs in five countries.

Summary for Neos Theraps Inc
International Patents:7
US Patents:7
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Neos Theraps Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neos Theraps Inc ADZENYS ER amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 204325-001 Sep 15, 2017 DISCN Yes No 9,265,737 See Plans and Pricing Y See Plans and Pricing
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-002 Jun 19, 2017 RX Yes No 9,089,496 See Plans and Pricing Y See Plans and Pricing
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-001 Jun 19, 2017 RX Yes No 8,840,924 See Plans and Pricing Y See Plans and Pricing
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-003 Jun 19, 2017 RX Yes Yes 11,166,947 See Plans and Pricing See Plans and Pricing
Neos Theraps Inc ADZENYS ER amphetamine SUSPENSION, EXTENDED RELEASE;ORAL 204325-001 Sep 15, 2017 DISCN Yes No 9,017,731 See Plans and Pricing Y See Plans and Pricing
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-002 Jun 19, 2017 RX Yes No 8,840,924 See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for Neos Theraps Inc Drugs

Country Patent Number Estimated Expiration
European Patent Office 2726066 See Plans and Pricing
European Patent Office 3585439 See Plans and Pricing
South Korea 20190107655 See Plans and Pricing
Australia 2017353921 See Plans and Pricing
Japan 2020504763 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2018085256 See Plans and Pricing
>Country >Patent Number >Estimated Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKesson
Dow
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.